Top 10 Companies in the Xanthan Gum for Pharmaceutical Market (2026): Market Leaders Powering Global Innovation

MARKET INSIGHTS

Global Xanthan Gum for Pharmaceutical market size was valued at USD 53.7 million in 2025 and is projected to reach USD 90.5 million by 2034, exhibiting a CAGR of 6.1% during the forecast period.

Xanthan gum is a high‑molecular‑weight polysaccharide produced through fermentation of glucose or sucrose by Xanthomonas campestris bacteria. In pharmaceutical applications, it functions as a versatile excipient with superior rheological properties, serving as a stabilizer, suspending agent, and viscosity modifier. Its unique shear‑thinning behavior and stability across wide pH ranges (3‑12) make it especially valuable for controlled‑release formulations and topical applications.

The market is expanding as demand for innovative drug delivery systems rises and the generics sector grows, with xanthan gum improving bioavailability of poorly soluble drugs. Price volatility remains a concern; after reaching decade‑high levels in Q1 2023, prices have stabilized but remain 18‑22% above 2020 averages. Leading producers such as Fufeng Group and CP Kelco are upgrading fermentation technology to offset raw material cost pressures, particularly from corn starch which accounts for 35‑40% of production costs.

Xanthan Gum for Pharmaceutical Market – View in Detailed Research Report

Top 10 Companies in the Xanthan Gum for Pharmaceutical Market (2026)

1. Fufeng Group

   Headquarters: Wuxi, China
   Key Offering: Pharmaceutical‑grade xanthan gum, tailored for suspensions, emulsions, and controlled‑release matrices

   Fufeng Group has secured a dominant share by integrating upstream fermentation with downstream purification, ensuring consistent rheological performance across batch sizes. Its vertically integrated supply chain mitigates feedstock price swings and supports rapid scaling of high‑viscosity grades.

   Sustainability & Growth Initiatives: Investment in next‑generation bioreactors that reduce energy consumption by 15% and a partnership with local corn growers to secure a stable raw material base.

   • Advanced fermentation lines with real‑time monitoring of viscosity and particle size.
   • ISO 9001 and GMP certification across all production sites.
   • Targeted R&D in bio‑ink formulations for 3D‑printed drug delivery.

2. CP Kelco

   Headquarters: U.S.
   Key Offering: High‑purity xanthan gum for oral suspensions, injectables, and ophthalmic solutions

   CP Kelco’s expansion of its Chinese facility in 2023 exemplifies its commitment to Asia‑Pacific manufacturing, reducing lead times for global clients. The company leverages proprietary strain engineering to boost yield by 18% while maintaining zero heavy metal content.

   Sustainability & Growth Initiatives: Launch of a closed‑loop water recycling system and a carbon‑neutral production target by 2030.

   • GMP‑certified lines for injectable and ophthalmic grades.
   • Strategic alliances with biotech firms to co‑develop high‑viscosity excipients.
   • Digital traceability platform for raw material sourcing.

3. Deosen Biochemical

   Headquarters: Shanghai, China
   Key Offering: Pharmaceutical‑grade xanthan gum with ultra‑low endotoxin levels for injectable use

   Deosen Biochemical focuses on stringent purification protocols, enabling compliance with Ph. Eur. endotoxin limits. Its specialized GMP lines support high‑volume production for biologics manufacturers.

   Sustainability & Growth Initiatives: Adoption of renewable energy sources for fermentation units and a waste‑to‑energy program for spent biomass.

   • Endotoxin‑free product portfolio for parenteral applications.
   • Collaborations with CDMOs to supply custom viscosities.
   • Continuous improvement of downstream processing to reduce solvent usage.

4. Jianlong Biotechnology

   Headquarters: Guangzhou, China
   Key Offering: Xanthan gum for oral and topical formulations, with emphasis on mucoadhesive properties

   Jianlong’s research team has developed a strain that yields a higher concentration of low‑molecular‑weight xanthan, enhancing film‑forming capability for topical gels.

   Sustainability & Growth Initiatives: Implementation of a closed‑loop nitrogen recycling system and a partnership with local farmers for sustainable corn sourcing.

   • High‑purity grades for topical and oral use.
   • Customized viscosity profiles for patient‑centric formulations.
   • Investment in AI‑driven process optimization.

5. Jungbunzlauer

   Headquarters: Switzerland
   Key Offering: Ultra‑clean xanthan gum for ophthalmic and injectable applications

   Jungbunzlauer’s European facilities adhere to the strict EU Pharmacopoeia, delivering products with zero pyrogens and heavy metals. Its precision fermentation technology allows rapid scale‑up for specialty grades.

   Sustainability & Growth Initiatives: Commitment to a circular economy through biomass valorization and a goal of 30% renewable energy use by 2030.

   • GMP‑certified lines for ophthalmic and injectable grades.
   • Partnerships with eye‑care manufacturers for bespoke formulations.
   • Digital supply chain transparency for raw material traceability.

6. IFF

   Headquarters: U.S.
   Key Offering: Xanthan gum for controlled‑release tablets and oral suspensions

   IFF’s robust R&D pipeline includes a proprietary xanthan blend that improves release kinetics in matrix systems, reducing dosing frequency for chronic therapies.

   Sustainability & Growth Initiatives: Reduction of CO₂ emissions by 20% across its U.S. plants and a commitment to sourcing 50% of raw materials from regenerative agriculture.

   • High‑purity grades compliant with USP‑NF.
   • Strategic alliances with generic manufacturers for cost‑effective supply.
   • Investment in digital twins for process simulation.

7. Hebei Xinhe Biochemical

   Headquarters: Hebei, China
   Key Offering: Cost‑effective xanthan gum for large‑volume oral suspensions

   Hebei Xinhe Biochemical focuses on delivering high‑quality excipients at competitive pricing, leveraging economies of scale in its fermentation facilities.

   Sustainability & Growth Initiatives: Implementation of a zero‑waste policy and a partnership with local agricultural cooperatives to secure sustainable corn supply.

   • Standard grades for oral and topical use.
   • Rapid turnaround for generic manufacturers.
   • Continuous improvement of downstream purification to meet global monographs.

8. Novozymes A/S

   Headquarters: Denmark
   Key Offering: Enzyme‑enhanced xanthan gum for improved bioavailability in oral formulations

   Novozymes leverages its enzymology expertise to produce xanthan gum with tailored chain lengths, enhancing dissolution rates for poorly soluble APIs.

   Sustainability & Growth Initiatives: Commitment to 100% renewable energy for production sites and a target of zero waste to landfill.

   • Enzyme‑modified grades for oral and topical applications.
   • Collaborations with formulation scientists to optimize release profiles.
   • Digital platform for real‑time quality monitoring.

9. Lallemand Inc.

   Headquarters: Canada
   Key Offering: Xanthan gum for nutraceuticals and oral suspensions

   Lallemand’s focus on functional food ingredients translates into a high‑purity xanthan line that meets both pharmaceutical and food regulatory standards.

   Sustainability & Growth Initiatives: Use of sustainable corn sourcing and a carbon‑offset program for logistics.

   • Dual‑regulatory compliant grades for pharma and food.
   • Strategic partnerships with nutraceutical manufacturers.
   • Investment in scalable fermentation for high‑volume demand.

10. BASF SE

    Headquarters: Germany
    Key Offering: High‑purity xanthan gum for ophthalmic and injectable products

    BASF’s expertise in polymer chemistry enables the production of xanthan with precise rheological properties suitable for sensitive drug delivery systems.

    Sustainability & Growth Initiatives: Goal of 50% renewable energy use across facilities and a circular economy strategy for raw material sourcing.

    • Ultra‑clean grades for ophthalmic and injectable use.
    • Collaborations with pharma companies for custom formulations.
    • Digital traceability for compliance and quality assurance.

Xanthan Gum for Pharmaceutical Market – View in Detailed Research Report

Xanthan Gum for Pharmaceutical Market – View in Detailed Research Report

OUTLOOK

As the pharmaceutical landscape continues to pivot toward patient‑centric therapies, the xanthan gum market is poised to deliver solutions that balance efficacy with manufacturability. The shift to biologics and injectables amplifies demand for excipients that maintain protein stability and syringeability, positioning xanthan gum as a critical component in pre‑filled syringes and biotherapeutic formulations. Concurrently, the generics sector’s focus on cost‑effective delivery systems will sustain volume growth, especially in emerging markets where affordable suspensions remain a priority.

FUTURE TRENDS

Several emerging directions are likely to shape the market trajectory:

• Integration of xanthan gum into bio‑inks and nanoparticle stabilizers for personalized 3D‑printed drugs, driven by a 12% CAGR in advanced delivery technologies.
• Acceleration of clean‑label initiatives, with formulators favoring natural polysaccharides over synthetic alternatives, especially in ophthalmic and topical products.
• Expansion of cryopreservation applications for gene therapies, where xanthan gum’s shear stability mitigates shear‑induced protein damage during freezing and thawing.
• Growth in controlled‑release coatings, enabled by advanced rheology that allows fine‑tuned release profiles across a range of pH environments.